ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN
This is research study to find out if a drug called ADCT-301 is safe and to look at how patients respond to the study drug after an allogeneic transplantation.

ADCT-301 will be administered on Days 1, 8 and 15 with blood tests following study drug infusion. Patients will have a bone marrow biopsy at the end of cycle 2/before cycle 3 to see how they are responding to the study drug.

Patients will be followed for approximately every 12 weeks from the last disease assessment for up to 1 year from completion of therapy.

There are risks to this study drug. Some risks include: decrease in certain blood cells, weight loss, loss of appetite, rash and Guillain-Barre syndrome, where the immune system attacks and damages nerves.
Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome (MDS)|Myeloproliferative Neoplasm (MDS/MPN)
DRUG: ADCT-301
Morphologic complete response rate of ADCT-301, Investigator report; efficacy rule, End of Study, up to 3 years|Safety of ADCT-301, Number of adverse events as measured by self report, up to 12 weeks (84 days) after the last dose
This is research study to find out if a drug called ADCT-301 is safe and to look at how patients respond to the study drug after an allogeneic transplantation.

ADCT-301 will be administered on Days 1, 8 and 15 with blood tests following study drug infusion. Patients will have a bone marrow biopsy at the end of cycle 2/before cycle 3 to see how they are responding to the study drug.

Patients will be followed for approximately every 12 weeks from the last disease assessment for up to 1 year from completion of therapy.

There are risks to this study drug. Some risks include: decrease in certain blood cells, weight loss, loss of appetite, rash and Guillain-Barre syndrome, where the immune system attacks and damages nerves.